Physician profile
Bethany Brown
NPI 1366848798
$865.82
in general payments reported to CMS, 2019-2025
16 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $151 · 2024: $324 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $162.13 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Stryker Corporation | $125.04 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.19 | 2025 | |
| Phathom Pharmaceuticals, INC. | $117.32 | 2024 | Voquezna |
| Novo Nordisk INC | $64.87 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $48.80 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $34.59 | 2024 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $32.92 | 2024 | Farxiga, Airsupra |
| Abbvie INC. | $31.39 | 2024-2025 | |
| Pfizer INC. | $25.76 | 2022 | |
| Janssen Biotech, INC. | $21.81 | 2025 | Tremfya |
| Amgen INC. | $17.94 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $16.87 | 2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $16.02 | 2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Janssen Pharmaceuticals, INC | $14.95 | 2025 | Spravato |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.22 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.